Aura Biosciences, Inc. (NASDAQ:AURA) Receives $22.75 Average Price Target from Brokerages

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have earned a consensus rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $22.75.

Several research firms have recently commented on AURA. JMP Securities set a $19.00 price target on shares of Aura Biosciences in a report on Wednesday, March 26th. Citigroup restated an “outperform” rating on shares of Aura Biosciences in a research report on Wednesday, March 26th. HC Wainwright set a $25.00 price target on Aura Biosciences in a research note on Tuesday, March 25th. Finally, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st.

Aura Biosciences Price Performance

AURA opened at $5.30 on Friday. The stock has a market capitalization of $266.19 million, a price-to-earnings ratio of -3.06 and a beta of 0.43. Aura Biosciences has a 12 month low of $4.84 and a 12 month high of $12.38. The business has a 50-day moving average of $6.96 and a two-hundred day moving average of $8.27.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). Equities research analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 23,045 shares of company stock valued at $177,242. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

Several hedge funds have recently added to or reduced their stakes in AURA. BNP Paribas Financial Markets purchased a new position in shares of Aura Biosciences in the 4th quarter worth $50,000. GAMMA Investing LLC increased its position in shares of Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock valued at $57,000 after purchasing an additional 9,573 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Aura Biosciences in the 4th quarter worth approximately $87,000. ProShare Advisors LLC purchased a new position in shares of Aura Biosciences in the fourth quarter worth approximately $127,000. Finally, Harvest Investment Services LLC bought a new stake in Aura Biosciences during the fourth quarter valued at approximately $133,000. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.